Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry ...Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events （MACE） and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 （98.7%） patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients （0.78%） had cardiac death, 6 （0.58%） suffered non-fatal myocardial infarction, and 46 （4.46%） underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 （0.97%） patients, and the rate of Academic Research Consortium （ARC） definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation.展开更多
文摘目的·分析急性非静脉曲张性上消化道出血(acute nonvariceal upper gastrointestinal bleeding,ANVUGIB)患者再出血的独立危险因素,构建再出血预测模型及风险评分系统。方法·收集2016年1月1日至2019年12月31日苏州大学附属第一医院收治的686例ANVUGIB患者的病例资料,记录患者的一般情况、临床表现、实验室检查结果、内镜下表现、病情转归等,并计算所有患者的内镜前Baylor、内镜后Baylor、Rockall、GBS (Glasgow Blatchford Score)、CSMCPI (Cedars-Sinai Medical Center Predictive Index)、AIMS65、MAP (ASH)评分。将所收集的病例按7∶3随机分成建模组(n=481)和验证组(n=205),使用建模组数据建立模型。将单因素分析中有意义的变量(P<0.1)纳入Logistic回归分析,探究再出血的独立危险因素,构建再出血风险预测模型并进行内部验证,分别评价建模组及验证组的区分度及校准度,最终将模型转换为风险评分系统。受试者操作特征(receiver operating characteristic,ROC)曲线效能的比较采用Delong统计法。结果·低收缩压,低血红蛋白水平,美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级>3级,内镜下呈现为血凝块、血管裸露、活动性出血是再出血的独立危险因素。预测模型的ROC曲线下面积(area under the curve,AUC)为0.892 (95%CI 0.838~0.946,P=0.001),Hosmer-Lemeshow检验P=0.934;内部验证AUC=0.915 (95%CI 0.851~0.980,P=0.001);Hosmer-Lemeshow检验P=0.871。该风险评分系统的AUC=0.882 (95%CI 0.823~0.942),对再出血的预测能力优于除MAP (ASH)评分以外的其余各项评分(均P<0.05)。结论·该研究建立的评分系统对ANVUGIB再出血具有良好的预测能力,具有一定的临床应用价值。
文摘Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events （MACE） and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 （98.7%） patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients （0.78%） had cardiac death, 6 （0.58%） suffered non-fatal myocardial infarction, and 46 （4.46%） underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 （0.97%） patients, and the rate of Academic Research Consortium （ARC） definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation.
